CoreWeave, Inc.
CRWVCoreWeave, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is between stages. Underneath, the last four quarters read mixed. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
CoreWeave, Inc. trades at $91.9, between stages. That is −2.6% against its own 200-day average. It sits at 30% of a 52-week range of $72 to $138. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (6 weeks and counting).
Today the stock is between stages. At $91.9 it trades −2.6% versus its 200-day average and sits at 30% of its 52-week range ($72–$138).
Against the market, two honest reads. Cumulative: over the last 1.3 years the stock moved +92% while the S&P 500 moved +53% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (6 weeks and counting; last ahead the week of 2026-06-26) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
P/E does not price CoreWeave, Inc. — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values CoreWeave, Inc. at 9.7× its FY25 revenue of $5.1 B.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
CoreWeave, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 6 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +167.2% | +535.4% | — | — |
| Stock price | −11.8% | — | — | — |
4-Factor Sector Score
33.9/100 — rank 25 of 28 in Software - Infrastructure · 61% evidence confidence
CoreWeave, Inc. scores 33.9 out of 100 against the 28 companies it is compared with in Software - Infrastructure, ranking 25. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 16 + 5.4 + 10 + 2.5 = 33.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
CoreWeave, Inc. reported $2.1 B of revenue in the Mar 26 quarter, +112.2% year on year. That is the 6th straight quarter of year-on-year growth. Over 3 years it has compounded at 535.4% a year. The last full year, FY25, came in at $5.1 B. The last four reported quarters add to $6.2 B.
FY25 revenue came in at $5.1 B (+167.2% on the year), capping 3 years at 535.4% compound. The latest quarter (Mar 26) printed $2.1 B, +112.2% year on year — the 6th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +139.6% growth against the decade's 535.4% — the current year is running slower than its own long-run rate.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
CoreWeave, Inc.'s operating margin is −6.7% in the Mar 26 quarter, −3.6 percentage points against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged −100.0% to 16.7%. The current quarter sits inside that band.
The latest quarter's operating margin is −6.7%, −3.6 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged −100.0%–16.7%.
🚨 Why the margin moved: operating margin went −3.6 pp year on year while gross margin went −8.1 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
CoreWeave, Inc. posted a net loss of $0.7 B in the Mar 26 quarter. The full FY25 year was a loss of $1.2 B. That loss is 35.6% of the quarter's revenue. The same quarter a year earlier lost $0.3 B. 10 of the last 10 reported quarters were loss-making.
Mar 26 profit was $−0.7 B, null year on year. On the full year, FY25 printed $−1.2 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
CoreWeave, Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $3.1 B of operating cash against $−1.2 B of profit. After $10.3 B of capital spending, $−7.3 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $3.1 B against reported profit of $−1.2 B, leaving free cash of $−7.3 B after $10.3 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
CoreWeave, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $22.0 B over the last 3 years. Averaged over those years that is 142.9% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $22.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
CoreWeave, Inc. earns a ROE of −35% in FY25. That is up from a trough of −66% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is −22.8% net margin on 0.10× asset turns.
FY25 ROE is −35%, recovered from a FY24 trough of −66% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): −22.8% net margin × 0.10× asset turns × 14.80× balance-sheet leverage ≈ −33.7% on equity. Margin does its share; leverage is a meaningful part of the equation.
Dividend
CoreWeave, Inc. pays no dividend. Across the last 10 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
CoreWeave, Inc. does not currently pay a dividend. Across the last 10 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
CoreWeave, Inc. carries total debt of $35.1 B against shareholder equity of $4.8 B as of Mar 26, a debt-to-equity of 7.38. On the annual view that ratio went from −15.38 in FY23 to 8.95 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $35.1 B against shareholder equity of $4.8 B — a debt-to-equity of 7.38. On the annual view, debt-to-equity went from −15.38 (FY23) to 8.95 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
20.5% of CoreWeave, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 2.2 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 20.5% of the float is sold short, and at typical trading volumes it would take about 2.2 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
CoreWeave, Inc.: the Z-score reads 0.36. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of 0.36 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads 0.36.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Fortinet, Inc.FTNT | 67.2/100Thin evidence · provisional58% evidence | LEADER | 21.4/35 Revenue — · PAT — · OPM change 1.9 pp 45% evidence | 17.8/25 ROCE 11.6% · OPM 31.4% 76% evidence | 9.4/20 P/E 54.1× · PEG — 15% evidence | 18.6/20 RS sector 39.5% · RS bench 54.1% · 1Y 126.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 17.8 + 9.4 + 18.6 = 67.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2NetApp, Inc.NTAP | 65.4/100Favorable setup85% evidence | LEADER | 19.4/35 Revenue 5.4% · PAT 7.6% · OPM change 7.2 pp 95% evidence | 16.1/25 ROCE 8.3% · OPM 27.3% 76% evidence | 11.9/20 P/E 17.1× · PEG 1.43 65% evidence | 18.0/20 RS sector 27.3% · RS bench 40.7% · 1Y 79.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 16.1 + 11.9 + 18 = 65.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Corpay, Inc.CPAY | 62.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 21.9/35 Revenue 18.2% · PAT 16.1% · OPM change 7.9 pp 83% evidence | 15.2/25 ROCE 5.8% · OPM 50.4% 76% evidence | 14.3/20 P/E 17.4× · PEG 1.01 65% evidence | 11.5/20 RS sector -0.1% · RS bench 11.2% · 1Y 31.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 15.2 + 14.3 + 11.5 = 62.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4VeriSign, Inc.VRSN | 60.5/100Thin evidence · provisional58% evidence | BASING | 22.2/35 Revenue — · PAT — · OPM change 1.1 pp 45% evidence | 21.6/25 ROCE 1141.8% · OPM 68.5% 76% evidence | 10.6/20 P/E 27.3× · PEG — 15% evidence | 6.1/20 RS sector -7.4% · RS bench 2.9% · 1Y 10%4 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 21.6 + 10.6 + 6.1 = 60.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Palantir Technologies Inc.PLTR | 60.0/100Mixed-positive evidence71% evidence | TURNING | 29.3/35 Revenue 67.7% · PAT 100% · OPM change 26.3 pp 83% evidence | 15.9/25 ROCE 10.3% · OPM 46.2% 76% evidence | 8.9/20 P/E 164.4× · PEG — 15% evidence | 5.9/20 RS sector -15.6% · RS bench -6.3% · 1Y -13.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 29.3 + 15.9 + 8.9 + 5.9 = 60 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -15.6% and the one-year return is -13.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 6CrowdStrike Holdings, Inc.CRWD | 55.7/100Mixed-positive evidence67% evidence | LEADER | 22.2/35 Revenue 23.2% · PAT — · OPM change 8.6 pp 71% evidence | 6.5/25 ROCE -0.5% · OPM -2.2% 76% evidence | 8.5/20 P/E 582.1× · PEG — 15% evidence | 18.5/20 RS sector 32.3% · RS bench 46% · 1Y 99%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 6.5 + 8.5 + 18.5 = 55.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Okta, Inc.OKTA | 54.4/100Mixed-positive evidence75% evidence | BREAKING OUT | 18.1/35 Revenue 11.8% · PAT 90% · OPM change 1.6 pp 95% evidence | 8.2/25 ROCE 0.8% · OPM 7.3% 76% evidence | 9.5/20 P/E 53.4× · PEG — 15% evidence | 18.6/20 RS sector 27.6% · RS bench 40.8% · 1Y 61.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 8.2 + 9.5 + 18.6 = 54.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8F5, Inc.FFIV | 53.7/100Thin evidence · provisional58% evidence | LEADER | 16.7/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 14.2/25 ROCE 4.4% · OPM 22.1% 76% evidence | 10.5/20 P/E 33.1× · PEG — 15% evidence | 12.3/20 RS sector 6.8% · RS bench 18.3% · 1Y 28.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 14.2 + 10.5 + 12.3 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Toast, Inc.TOST | 53.2/100Mixed-positive evidence71% evidence | TURNING | 25.0/35 Revenue 23.4% · PAT 100% · OPM change 3.5 pp 83% evidence | 10.7/25 ROCE 5.9% · OPM 6.7% 76% evidence | 9.9/20 P/E 40.8× · PEG — 15% evidence | 7.6/20 RS sector -15.1% · RS bench -6% · 1Y -21.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 25 + 10.7 + 9.9 + 7.6 = 53.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10GoDaddy Inc.GDDY | 52.0/100Thin evidence · provisional58% evidence | ASLEEP | 21.2/35 Revenue — · PAT — · OPM change 3.8 pp 45% evidence | 15.3/25 ROCE 6.8% · OPM 24.5% 76% evidence | 11.4/20 P/E 12.6× · PEG — 15% evidence | 4.1/20 RS sector -33% · RS bench -26% · 1Y -33.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 15.3 + 11.4 + 4.1 = 52 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Microsoft CorporationMSFT | 51.5/100Thin evidence · provisional58% evidence | TURNING | 16.7/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence | 16.2/25 ROCE 7.6% · OPM 46.3% 76% evidence | 10.8/20 P/E 20.8× · PEG — 15% evidence | 7.8/20 RS sector -11.2% · RS bench -1.5% · 1Y -5.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 16.2 + 10.8 + 7.8 = 51.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12DigitalOcean Holdings, Inc.DOCN | 51.2/100Mixed-positive evidence71% evidence | FADING | 16.8/35 Revenue 17.7% · PAT 100% · OPM change -3.7 pp 83% evidence | 10.7/25 ROCE 2.2% · OPM 14.2% 76% evidence | 10.4/20 P/E 37.5× · PEG — 15% evidence | 13.3/20 RS sector 35.2% · RS bench 50.5% · 1Y 290%11 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 10.7 + 10.4 + 13.3 = 51.2 · Decision use: Price leads the evidence: RS versus the benchmark is 50.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13Nutanix, Inc.NTNX | 50.6/100Mixed-positive evidence75% evidence | BREAKING OUT | 19.0/35 Revenue -1.9% · PAT 100% · OPM change 5.2 pp 95% evidence | 11.0/25 ROCE 3.7% · OPM 19.3% 76% evidence | 9.8/20 P/E 43× · PEG — 15% evidence | 10.8/20 RS sector -6.3% · RS bench 2.9% · 1Y -14.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 11 + 9.8 + 10.8 = 50.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Rubrik, Inc.RBRK | 50.1/100Mixed-positive evidence64% evidence | BREAKING OUT | 25.7/35 Revenue 45.9% · PAT — · OPM change 19.8 pp 71% evidence | 3.1/25 ROCE -5.3% · OPM -13.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.3/20 RS sector -5.3% · RS bench 4.2% · 1Y -7.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 25.7 + 3.1 + 10 + 11.3 = 50.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Samsara Inc.IOT | 49.3/100Mixed-negative evidence67% evidence | BREAKING OUT | 24.5/35 Revenue 29.6% · PAT — · OPM change 10.6 pp 71% evidence | 7.1/25 ROCE 0.5% · OPM 1.5% 76% evidence | 8.6/20 P/E 304.9× · PEG — 15% evidence | 9.1/20 RS sector -9.4% · RS bench 0.2% · 1Y 14.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 7.1 + 8.6 + 9.1 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Gen Digital Inc.GEN | 48.8/100Mixed-negative evidence74% evidence | BREAKING OUT | 17.4/35 Revenue 27.1% · PAT 51.3% · OPM change -6.4 pp 62% evidence | 15.8/25 ROCE 6.3% · OPM 62.6% 76% evidence | 7.1/20 P/E 12× · PEG 2.71 65% evidence | 8.5/20 RS sector -9.5% · RS bench 0.1% · 1Y -7.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 15.8 + 7.1 + 8.5 = 48.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Cloudflare, Inc.NET | 48.8/100Mixed-negative evidence61% evidence | BREAKING OUT | 18.0/35 Revenue 31.6% · PAT — · OPM change 1.4 pp 62% evidence | 3.5/25 ROCE -1.9% · OPM -9.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 17.3/20 RS sector 14.6% · RS bench 26.9% · 1Y 47.3%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 3.5 + 10 + 17.3 = 48.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Twilio Inc.TWLO | 47.7/100Mixed-negative evidence64% evidence | FADING | 18.5/35 Revenue 15.6% · PAT — · OPM change 5.7 pp 62% evidence | 8.5/25 ROCE 1.2% · OPM 7.7% 76% evidence | 8.8/20 P/E 196.6× · PEG — 15% evidence | 11.9/20 RS sector 10.6% · RS bench 22.8% · 1Y 96.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 8.5 + 8.8 + 11.9 = 47.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Akamai Technologies, Inc.AKAM | 45.7/100Mixed-negative evidence81% evidence | FADING | 10.0/35 Revenue 6.1% · PAT -4% · OPM change -4.5 pp 83% evidence | 11.6/25 ROCE 1.2% · OPM 10.7% 76% evidence | 15.2/20 P/E 38.7× · PEG 0.7 65% evidence | 8.9/20 RS sector -0.7% · RS bench 10.8% · 1Y 74.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 10 + 11.6 + 15.2 + 8.9 = 45.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 20MongoDB, Inc.MDB | 44.8/100Mixed-negative evidence64% evidence | BREAKING OUT | 20.9/35 Revenue 23.7% · PAT — · OPM change 6.2 pp 71% evidence | 5.0/25 ROCE -0.8% · OPM -3.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.9/20 RS sector -6.3% · RS bench 4.2% · 1Y 81.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 5 + 10 + 8.9 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Check Point Software Technologies Ltd.CHKP | 43.3/100Thin evidence · provisional58% evidence | TURNING | 13.9/35 Revenue — · PAT — · OPM change -3 pp 45% evidence | 14.2/25 ROCE 3.8% · OPM 27.7% 76% evidence | 11.2/20 P/E 13.5× · PEG — 15% evidence | 4.0/20 RS sector -39.5% · RS bench -32.8% · 1Y -32.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 14.2 + 11.2 + 4 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Oracle CorporationORCL | 42.2/100Mixed-negative evidence85% evidence | ASLEEP | 16.1/35 Revenue 17.4% · PAT 37.3% · OPM change -0.1 pp 95% evidence | 13.1/25 ROCE 3.4% · OPM 32% 76% evidence | 12.4/20 P/E 38.7× · PEG 1.13 65% evidence | 0.6/20 RS sector -39.7% · RS bench -33.5% · 1Y -41.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 13.1 + 12.4 + 0.6 = 42.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Palo Alto Networks, Inc.PANW | 40.1/100Mixed-negative evidence85% evidence | LEADER | 7.9/35 Revenue 19.5% · PAT -31.9% · OPM change -15.7 pp 95% evidence | 6.8/25 ROCE -0.7% · OPM -6.1% 76% evidence | 5.5/20 P/E 147× · PEG 2.62 65% evidence | 19.9/20 RS sector 40.1% · RS bench 54.3% · 1Y 119.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 6.8 + 5.5 + 19.9 = 40.1 · Decision use: Price leads the evidence: RS versus the benchmark is 54.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 24Zscaler, Inc.ZS | 35.8/100Mixed-negative evidence64% evidence | FADING | 16.4/35 Revenue 24.6% · PAT — · OPM change 0.2 pp 71% evidence | 4.5/25 ROCE -0.9% · OPM -3.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.9/20 RS sector -35.7% · RS bench -29.3% · 1Y -39.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 4.5 + 10 + 4.9 = 35.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25CoreWeave, Inc.this pageCRWV | 33.9/100Adverse evidence61% evidence | ASLEEP | 16.0/35 Revenue 100% · PAT — · OPM change -4.2 pp 62% evidence | 5.4/25 ROCE -0.5% · OPM -6.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.5/20 RS sector -23.5% · RS bench -15.1% · 1Y -29.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 5.4 + 10 + 2.5 = 33.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Block, Inc.XYZ | 31.0/100Adverse evidence71% evidence | BREAKING OUT | 5.2/35 Revenue 2.3% · PAT -68.8% · OPM change -8.5 pp 83% evidence | 6.5/25 ROCE -0.6% · OPM -2.8% 76% evidence | 9.6/20 P/E 47× · PEG — 15% evidence | 9.7/20 RS sector -1.2% · RS bench 9.4% · 1Y 15.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 5.2 + 6.5 + 9.6 + 9.7 = 31 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Synopsys, Inc.SNPS | 30.4/100Adverse evidence85% evidence | ASLEEP | 10.3/35 Revenue 39.5% · PAT -41.8% · OPM change -18.2 pp 95% evidence | 9.8/25 ROCE 0.4% · OPM 5.3% 76% evidence | 8.4/20 P/E 111.7× · PEG 1.75 65% evidence | 1.9/20 RS sector -29.2% · RS bench -21.4% · 1Y -34.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10.3 + 9.8 + 8.4 + 1.9 = 30.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Cerebras Systems Inc.CBRS | 49.8/100Thin evidence · provisional41% evidence | 25.6/35 Revenue 86.1% · PAT — · OPM change 20.8 pp 62% evidence | 4.2/25 ROCE -0.9% · OPM -7.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 25.6 + 4.2 + 10 + 10 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is CoreWeave, Inc.'s stock price today?
CoreWeave, Inc. trades at $91.9, −11.8% over the past year. The company is valued at $50.0 B. The stock sits at 30% of its 52-week range of $72–$138, −2.6% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 6 weeks. — as of 5 August 2026.
What were CoreWeave, Inc.'s latest quarterly results?
CoreWeave, Inc. reported revenue of $2.1 B and a net loss of $0.7 B for the Mar 26 quarter. Earnings per share were $−1.40. The operating margin was −6.7%, 3.6 pp lower than a year earlier. — as of 5 August 2026.
What is CoreWeave, Inc.'s revenue?
CoreWeave, Inc. reported revenue of $2.1 B in the Mar 26 quarter, +112.2% year on year. For the full FY25 fiscal year, revenue was $5.1 B (+167.2%). Over the last 3 years revenue compounded at 535.4% a year. — as of 5 August 2026.
What is CoreWeave, Inc.'s profit?
CoreWeave, Inc. earned $−0.7 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−1.2 B. The operating margin ran −6.7% in the latest quarter. — as of 5 August 2026.
What is CoreWeave, Inc.'s market cap?
CoreWeave, Inc.'s market capitalisation is $50.0 B at a stock price of $91.9. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does CoreWeave, Inc. pay a dividend?
No — CoreWeave, Inc. has declared no dividend per share in any of its last 10 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
How is CoreWeave, Inc. performing?
CoreWeave, Inc.'s latest readings are below. Against the S&P 500 it has been behind on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
Is CoreWeave, Inc. beating the market?
Not lately — on a trailing-13-week view CoreWeave, Inc. is currently behind the S&P 500 (6 weeks and counting; last ahead the week of 2026-06-26), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.3 years the stock moved +92% against the S&P 500's +53% — ahead of the index over the full window. — as of 5 August 2026.
Will CoreWeave, Inc.'s stock price go up?
This page publishes no price forecast for CoreWeave, Inc. What it measures instead: the stock price is $91.9. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against CoreWeave, Inc.?
Yes — short interest is 20.5% of CoreWeave, Inc.'s tradable float, about 2.2 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does CoreWeave, Inc. have too much debt?
It carries real leverage — CoreWeave, Inc.'s debt-to-equity is 7.39. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is CoreWeave, Inc.'s capex?
CoreWeave, Inc. spent $22.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $10.3 B. — as of 5 August 2026.
What is CoreWeave, Inc.'s cash flow?
CoreWeave, Inc. generated $3.1 B of operating cash flow in FY25 and $−7.3 B of free cash flow after $10.3 B of capital spending. Reported profit that year was $−1.2 B, so operating cash ran ahead of profit. — as of 5 August 2026.
How financially safe is CoreWeave, Inc.?
On the balance sheet, the Z-score reads 0.36 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 5 August 2026.
Where is CoreWeave, Inc. in its business cycle?
CoreWeave, Inc.'s FY25 operating margin was −1.0%, against a 4-year band of −100.0%–16.7%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran −6.7%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the CoreWeave, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is CoreWeave, Inc. a stock worth studying right now?
This is not investment advice. The machine read: CoreWeave, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.